Andipal, tablets 20 pcs

Pharmacotherapeutic group: analgesic combination medicine (analgesic non-narcotic + antispasmodic + barbiturate).

ATX code: N02BB72

Pharmacological properties

Pharmacodynamics

p>Combination drug, has vasodilatory, analgesic, antispasmodic and sedative effects.

Andipal, as an antispasmodic agent, is used for spasms of peripheral blood vessels and cerebral vessels.

Lowering total peripheral resistance, acting on the arterioles, the drug reduces blood pressure and improves collateral circulation.

The combination of myotropic antispasmodics (bendazole and papaverine) with sodium metamizole increases the analgesic effect of the latter in headache and migraine. The presence of phenobarbital in the drug contributes to the sedative effect and enhances the action of the other components.

Pharmacokinetics

Sodium metamizole:is well and quickly absorbed into the gastrointestinal tract. In the intestinal wall it is hydrolyzed to form the active metabolite, unchanged sodium metamizole is absent in blood (only after intravenous administration a small concentration is found in plasma). Binding of active metabolite with plasma proteins is 50-60%. It is metabolized in the liver and excreted by the kidneys. In therapeutic doses penetrates into breast milk.

Papaverine:absorption depends on the dosage form. The bioavailability on average is 54%. Binding with plasma proteins – 90%. Well distributed, penetrates through histohematic barriers. It is metabolized in liver. Half-life (T_1/2) is 0.5-2 hours (may be prolonged up to 24 hours). It is excreted by the kidneys as metabolites. Completely eliminated from the blood by hemodialysis.

Phenobarbital:when ingested, phenobarbital is completely but relatively slowly absorbed. The maximum concentration in the blood is observed 1-2 h after ingestion. About 50% is bound to plasma proteins. The drug is evenly distributed in different organs and tissues; lower concentrations are found in brain tissues. The half-life in adults is 2-4 days. It is excreted from the body slowly, which creates conditions for cumulation. It is metabolized by liver microsomal enzymes. It is excreted by kidneys as inactive metabolites and 25-50% – unchanged.

Indications

Pain syndrome (mild to moderately pronounced) in spasms of smooth muscles of internal organs:

• renal colic, biliary colic, intestinal colic;
• biliary dyskinesia, postcholecystectomy syndrome;
• spasm of the ureters and bladder;
• algodysmenorrhea.

Spasm of cerebral vessels, migraine.

As an adjunctive medicine: pain syndrome after surgery and diagnostic procedures.

Active ingredient

Bendazol, Sodium Metamizole, Papaverine, Phenobarbital

Composition

Per tablet:

Active ingredients:

Sodium metamizole (analgin) – 250 mg,

phenobarbital – 20 mg,

bendazole (dibazole) – 20 mg,

papaverine hydrochloride – 20 mg.

Excipients:

potato starch – 46 mg,

talc – 7 mg,

stearic acid – 3 mg,

calcium stearate – 4 mg.

How to take, the dosage

Orally, adults and children over 8 years old take 1 tablet 2-3 times a day. Duration of use without medical advice should not exceed 3 days.

Interaction

Combination with nitrates (nitroglycerin, nitrosorbide, Sustac etc.), calcium channel blockers (nifedipine, corinfar etc.), beta-adrenoblockers (anapriline, metoprolol, thalinolol etc.), ganglioblockers (pentamine etc.), diuretics (furosemide, hypothiazide etc.), myotropic antispasmodics (dipyridamole, eufylline etc.) increases the hypotensive effect of these drugs.

Simultaneous use with other non-narcotic analgesics may lead to mutual enhancement of toxic effects. Concomitant use with adsorbents, astringents and coating agents reduces absorption of the drug in the gastrointestinal tract.

Special Instructions

In case of long-term (more than 7 days) use the peripheral blood picture and functional state of the liver should be controlled.

In the absence of the effect within 3 days the drug administration should be stopped and the patient should consult a physician.

During the treatment it is necessary to refrain from potentially hazardous activities that require high concentration and quick psychomotor reactions.

The drug should be used by children and adolescents under 18 years old only by prescription.

Contraindications

• Hypersensitivity (including. Hypersensitivity (including to pyrazolone derivatives);
• inhibition of medullary hematopoiesis;
• expressed hepatic and/or renal insufficiency;
• deficiency of glucose-6-phosphate dehydrogenase;
• children
• under 8 years of age, pregnancy, period of tachyarrhythmia, severe angina pectoris.Children under 8 years of age, pregnancy, lactation, tachyarrhythmias, severe angina pectoris, collapse, decompensated chronic heart failure;
• closed angle glaucoma;
• prostate hyperplasia;
• intestinal obstruction, megacolon.

.

Side effects

Allergic reactions.

Central nervous system: drowsiness, decreased rate of psychomotor reactions.

Gastrointestinal tract: nausea, constipation.

Cardiovascular system: arterial hypotension.

In long-term use: leukopenia, agranulocytosis, liver and kidney function disorders.

Similarities

Andipal